This story was initially printed by Knowable Journal.
At age 49, Jan Janisch-Hanzlik’s a number of sclerosis was destroying her freedom to dwell the life she wished. She gave up her energetic nursing job for a desk function. Frequent falls made her afraid to hold her grandchildren. She needed to transfer to an even bigger home to make room for the wheelchair she feared she would possibly find yourself needing full-time.
Even one of the best out there medicine wasn’t enhancing Janisch-Hanzlik’s signs, and he or she nervous they’d solely worsen. So when she discovered a few trial of CAR T cell remedy on the College of Nebraska Medical Heart in Omaha, near town of Blair the place she lives, she phoned the clinic each different month till they have been able to enroll her as the primary affected person.
Initially designed to focus on and wipe out most cancers by reprogramming the affected person’s immune cells, CAR T is now being supplied to sufferers in a whole bunch of medical trials for autoimmune situations like a number of sclerosis, lupus, Graves’ illness, vasculitis, and lots of others. The hope is that CAR T can duplicate the success it has demonstrated in a spread of blood cancers by looking down and eliminating cells that concentrate on the self in autoimmune illnesses. This could basically reset the physique’s defenses to a state just like the one which existed earlier than the illness took maintain.
However together with CAR T’s promise come dangers, questions and challenges. There’s uncertainty about how effectively it can work for autoimmunity and the way lengthy any advantages would possibly final, in addition to what long-term uncomfortable side effects would possibly come up. Janisch-Hanzlik knew this when she sat all the way down to obtain the experimental therapy on June 9, 2025; she felt a mixture of hope and worry realizing that she could be spending the subsequent week being monitored for uncomfortable side effects together with harmful irritation.
Along with her medical experience and want to pioneer a brand new therapy, Janisch-Hanzlik’s two younger grandchildren helped encourage her pursuit of a therapy with identified dangers and unsure advantages. As a result of a number of sclerosis has a genetic element, Janisch-Hanzlik knew that they’ve an elevated likelihood of going via the identical wrestle she has. “I might need to have the ability to say I did the whole lot that I presumably might to forestall them, or anybody else, from having one thing like this,” she says.
From Most cancers to Autoimmunity
The primary CAR T most cancers therapy was permitted by the Meals and Drug Administration in 2017 for an aggressive type of leukemia. Since then, the highly effective and intensive therapy has resulted in long-term remission for a lot of most cancers sufferers.
The fundamental premise of CAR T is to activate the ability of key immune cells referred to as T cells. T cells usually acknowledge different cells which were contaminated by a virus or bacterium, or are in any other case irregular, and both destroy them or recruit different components of the immune system to take action.
In CAR T for most cancers, scientists engineer these T cells to particularly hunt and destroy malignant cells. The know-how received its begin when most cancers researchers discovered the way to take out a affected person’s personal T cells, insert DNA directions for a “chimeric antigen receptor,” or CAR, and put them again into the particular person’s circulation. The CAR, which sits on the T cell’s floor and latches on to a particular molecular companion on the floor of cancerous cells, prompts the T cell to assault.
At this time, CAR T cells are mostly programmed to assault B cells, one other key immune participant. B cells are usually accountable for making antibodies, however in sure blood cancers, they proliferate uncontrolled. By giving T cells a CAR that acknowledges one in every of a few molecules distinctive to the B cell floor, the cells are reprogrammed to seek out and remove these cancerous cells.
B cells are also the central downside in lots of autoimmune situations: They mistakenly make antibodies in opposition to regular tissues as an alternative of in opposition to invading pathogens. In order CAR T started to succeed in opposition to B cell cancers, it didn’t take lengthy for docs to purpose that CAR T remedy may also be capable to wipe out unhealthy B cells in individuals with autoimmunity.
A German crew pioneered autoimmune CAR T in a girl with lupus, reporting constructive outcomes in 2021. Since then, that crew and others have labored to translate the oncology success of CAR T to deal with a broad spectrum of autoimmune illnesses.
“I feel it’s a recreation changer,” says Amanda Piquet, an autoimmune neurologist on the College of Colorado Anschutz in Aurora. Piquet is evaluating CAR T remedy for a uncommon and poorly understood autoimmune situation referred to as stiff particular person syndrome, with signs together with muscle stiffness and painful spasms. There isn’t any FDA-approved therapy. When she heard about an organization referred to as Kyverna that was testing CAR T cell remedy within the syndrome, she thought it was “an ideal alternative.”
The examine she led, which reported preliminary outcomes in December 2025, examined a single dose of CAR T in 26 individuals. Earlier than the therapy, many contributors struggled with a gradual, mechanical gait, and 12 used assistive units corresponding to walkers and canes. Most sufferers have been capable of stroll sooner by 16 weeks post-treatment, and eight not wanted their assistive units for brief distances. In April, the corporate reported that each one 26 sufferers, as of their final follow-up appointment 4 to 12 months out from the remedy, have been not utilizing some other immunotherapies.
Dangers and Uncertainties
Regardless of such hanging outcomes, reprogramming the immune system is not any easy matter. In early therapy of most cancers sufferers, CAR T cells produced life-threatening uncomfortable side effects, as outlined in a 2026 article within the Annual Assessment of Drugs. As CAR T cells assault their targets, the related irritation may cause signs like excessive fevers and low blood stress. If that irritation reaches the mind, it could trigger further issues corresponding to confusion and drowsiness.
Fortuitously, physicians now have a decade’s price of expertise recognizing and treating these issues. “They’re definitely reversible and don’t trigger long-term harm more often than not,” says Emily Littlejohn, a rheumatologist on the Cleveland Clinic.
Physicians and sufferers additionally should deal with decreased immunity as each a aspect impact of the therapy and its desired consequence. In CAR T therapy, docs sometimes use highly effective chemotherapy medicine to briefly cut back the physique’s immune cell inhabitants to make room for the brand new, engineered cells, leaving sufferers briefly immunosuppressed. And if the therapy works, it can decimate B cell populations. Sufferers may be susceptible to infections for as much as a yr after therapy, says Littlejohn.
These results are manageable with preventive antibiotics, antivirals, and vaccines. Sufferers additionally retain antibodies that their B cells made earlier than the therapy, which give residual safety for just a few months. And for causes that aren’t but totally understood, CAR T appears to go away older B cells, which give immune reminiscence of previous infections, intact in some circumstances. One examine discovered that autoimmune sufferers handled with CAR T nonetheless made antibodies for illnesses they’d been beforehand vaccinated in opposition to, like rooster pox and measles. These are indicators that the therapy didn’t utterly return the immune system to its manufacturing facility settings.
When evaluating CAR T threat, it’s vital to contemplate that many present therapies for autoimmune illness additionally suppress the immune system for so long as an individual takes them, specialists observe.
However there are different potential CAR T dangers for autoimmune sufferers. In February, FDA officers printed a paper endorsing CAR T’s potential in autoimmunity however warning of “unpredictable long-term toxicity.” CAR T therapy for most cancers, the authors famous, has been linked to numerous long-term points corresponding to Parkinson’s illness. There have additionally been circumstances the place the bioengineered cells themselves turned malignant, inflicting new, T cell-based cancers.
Inflicting a secondary most cancers could also be an appropriate threat when treating a life-threatening most cancers, however in all probability not for autoimmunity, says Matt Lunning, medical director for gene and mobile remedy at Nebraska Drugs in Omaha. How one can stability the danger between the impacts of an autoimmune illness, which may vary extensively in severity, and the difficult-to-quantify threat of future uncomfortable side effects or cancers stays a significant open query.
Researchers are already engaged on second- and third-generation variations of CAR T that they anticipate to be safer for each most cancers and autoimmunity. For instance, James Howard, a neuromuscular neurologist on the College of North Carolina at Chapel Hill, is testing a know-how from an organization referred to as Cartesian Therapeutics that encodes the CAR utilizing molecules of mRNA, the short-lived genetic messenger utilized in Covid-19 vaccines, as an alternative of long-lasting DNA. The CAR T cells ought to wipe out B cells for less than so long as the mRNA persists, then lose their B cell-targeting skills. With no likelihood for genetically modified T cells to hold round long-term, there ought to be no most cancers threat.
One other plus of Cartesian’s method: Physicians infuse these T cells in ample numbers that they don’t want to breed within the affected person’s physique, which Howard thinks reduces threat for irritation. In a current trial, 15 individuals with autoimmune illnesses acquired the Cartesian CAR T therapy; two-thirds noticed their signs enhance and none suffered long-term critical uncomfortable side effects.
Treating CAR T Sticker Shock
Past uncomfortable side effects, the opposite main problem going through CAR T remedy is its price ticket, which reaches a whole bunch of hundreds of {dollars} together with hospital stays, cell engineering, and different bills.
The therapy would possible be cheaper, and less complicated, if scientists might remove the necessity for customized engineering of every affected person’s personal cells and as an alternative use donor cells, or if they might minimize out the step of engineering and rising the cells in a laboratory. Lunning says he’s eyeing up-and-coming procedures that will modify an individual’s T cells inside their very own physique as an alternative of doing the genetic engineering in a lab.
Researchers are even farther together with a model of CAR T that makes use of wholesome donors as a supply of T cells. These might then be utilized by many sufferers in an “off-the-shelf” method. It’s a technique that has its personal challenges, due to the immune mismatch between donor and affected person cells that will cause them to assault one another. This downside may be overcome with further genetic modifications to the donated T cells that stop recipient and donor methods from recognizing one another as international, says Bing Du, an immunologist at East China Regular College in Shanghai who’s amongst many researchers engaged on this method. Du estimates a lab might make CAR T cells for greater than 1,000 sufferers from a single donor’s blood cells, at vital price financial savings.
This type of off-the-shelf CAR T remedy is what Janisch-Hanzlik of Nebraska acquired, underneath Lunning’s care, in 2025. The examine organizers at TG Therapeutics anticipate to finish their analysis in early 2029.
Janisch-Hanzlik ended up crusing via the follow-up with out uncomfortable side effects. A few months after the infusion, she was watching TV when she seen she not wanted particular glasses to appropriate double imaginative and prescient. She began forgetting to deliver her cane when transferring about her home or going grocery procuring; she didn’t want it. Now, practically a yr because the therapy, she not often falls and not requires a day by day, three-hour nap. She lately loved a visit to the Grand Canyon and appears ahead to spending extra time together with her grandchildren.
She does nonetheless have signs, together with weak point in her proper leg, numbness and tingling in her toes, and issue discovering the appropriate phrase when talking. She asks her docs in the event that they assume she’s going to get higher, keep the identical or worsen once more.
“I’ve been advised so many occasions, ‘We don’t know, you’re the primary. We’re simply going to have to attend and see,’” she says. “I undoubtedly am grateful for day by day I’ve.”
This text initially appeared in Knowable Journal, an impartial journalistic endeavor from Annual Evaluations. Join the e-newsletter.
